Urge your members of Congress to support continued medical research funding
ASH is interested in addressing unmet needs in genomic profiling of malignant and non-malignant hematologic diseases. The Society is exploring opportunities to match sequencing services to projects at a level of maturity to benefit from specific types of sequencing.
If you are interested in this opportunity, please submit a letter of intent (LOI) providing details on the hematologic disorders in your study and the number of accessible samples that may be suitable for sequencing by April 24, 2017.
The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.
Blood Advances, the first journal to join the Blood family in 70 years, is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, the inaugural issue made it's debut in December at the 58th ASH Annual Meeting and Exposition in San Diego.
Explore programs offered by ASH to support clinical and scientific hematology research
ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Dr. Linkins discusses a study that supports moving away from conducting thrombophilic work-ups in pregnant women who experience placenta-mediated complications.
Dr. Jacobson looks at targeting the b and t lymphocyte attenuator through engineered soluble herpes virus entry mediator delivery.
Dr. Hoggatt discusses hematopoietic stem cells' capacity for lifelong production of blood cells as well as the ability to count the number of self-renewal divisions they have undergone, and have a maximal limit of four.
The House of Representatives released legislation, titled
the “American Health Care Act,” to repeal the Affordable Care Act. As
written, ASH has serious concerns that this legislation will reduce overall
access to coverage and treatment and would greatly impact patients with
hematologic diseases and disorders.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology